JP7181881B2 - プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 - Google Patents

プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 Download PDF

Info

Publication number
JP7181881B2
JP7181881B2 JP2019542356A JP2019542356A JP7181881B2 JP 7181881 B2 JP7181881 B2 JP 7181881B2 JP 2019542356 A JP2019542356 A JP 2019542356A JP 2019542356 A JP2019542356 A JP 2019542356A JP 7181881 B2 JP7181881 B2 JP 7181881B2
Authority
JP
Japan
Prior art keywords
days
subject
pharmaceutical composition
rnai agent
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2019542356A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019531357A (ja
JP2019531357A5 (enExample
Inventor
ペーテル・ワインガールト
デイヴィッド・カレンド
Original Assignee
ザ メディシンズ カンパニー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=60388127&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=JP7181881(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ザ メディシンズ カンパニー filed Critical ザ メディシンズ カンパニー
Publication of JP2019531357A publication Critical patent/JP2019531357A/ja
Publication of JP2019531357A5 publication Critical patent/JP2019531357A5/ja
Priority to JP2022068684A priority Critical patent/JP7566815B2/ja
Application granted granted Critical
Publication of JP7181881B2 publication Critical patent/JP7181881B2/ja
Priority to JP2024173304A priority patent/JP7850215B2/ja
Priority to JP2025258789A priority patent/JP2026062719A/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A61K31/713—Double-stranded nucleic acids or oligonucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0066—Manipulation of the nucleic acid to modify its expression pattern, e.g. enhance its duration of expression, achieved by the presence of particular introns in the delivered nucleic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H21/00—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids
    • C07H21/02—Compounds containing two or more mononucleotide units having separate phosphate or polyphosphate groups linked by saccharide radicals of nucleoside groups, e.g. nucleic acids with ribosyl as saccharide radical
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Y—ENZYMES
    • C12Y304/00—Hydrolases acting on peptide bonds, i.e. peptidases (3.4)
    • C12Y304/21—Serine endopeptidases (3.4.21)
    • C12Y304/21061—Kexin (3.4.21.61), i.e. proprotein convertase subtilisin/kexin type 9
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/14—Type of nucleic acid interfering nucleic acids [NA]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/351—Conjugate
    • C12N2310/3515—Lipophilic moiety, e.g. cholesterol
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/352—Nature of the modification linked to the nucleic acid via a carbon atom
    • C12N2310/3521—Methyl
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/35—Nature of the modification
    • C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
    • C12N2310/3533—Halogen

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Urology & Nephrology (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Virology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Enzymes And Modification Thereof (AREA)
JP2019542356A 2016-10-18 2017-10-18 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法 Active JP7181881B2 (ja)

Priority Applications (3)

Application Number Priority Date Filing Date Title
JP2022068684A JP7566815B2 (ja) 2016-10-18 2022-04-19 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2024173304A JP7850215B2 (ja) 2016-10-18 2024-10-02 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2025258789A JP2026062719A (ja) 2016-10-18 2025-12-17 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201662409816P 2016-10-18 2016-10-18
US62/409,816 2016-10-18
US201662422028P 2016-11-14 2016-11-14
US62/422,028 2016-11-14
US201762472525P 2017-03-16 2017-03-16
US62/472,525 2017-03-16
US201762550426P 2017-08-25 2017-08-25
US62/550,426 2017-08-25
PCT/US2017/057218 WO2018075658A1 (en) 2016-10-18 2017-10-18 Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2022068684A Division JP7566815B2 (ja) 2016-10-18 2022-04-19 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法

Publications (3)

Publication Number Publication Date
JP2019531357A JP2019531357A (ja) 2019-10-31
JP2019531357A5 JP2019531357A5 (enExample) 2021-10-21
JP7181881B2 true JP7181881B2 (ja) 2022-12-01

Family

ID=60388127

Family Applications (4)

Application Number Title Priority Date Filing Date
JP2019542356A Active JP7181881B2 (ja) 2016-10-18 2017-10-18 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2022068684A Active JP7566815B2 (ja) 2016-10-18 2022-04-19 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2024173304A Active JP7850215B2 (ja) 2016-10-18 2024-10-02 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2025258789A Pending JP2026062719A (ja) 2016-10-18 2025-12-17 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法

Family Applications After (3)

Application Number Title Priority Date Filing Date
JP2022068684A Active JP7566815B2 (ja) 2016-10-18 2022-04-19 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2024173304A Active JP7850215B2 (ja) 2016-10-18 2024-10-02 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP2025258789A Pending JP2026062719A (ja) 2016-10-18 2025-12-17 プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法

Country Status (21)

Country Link
US (3) US20180104360A1 (enExample)
EP (2) EP3529360B1 (enExample)
JP (4) JP7181881B2 (enExample)
KR (3) KR20240067272A (enExample)
CN (4) CN119345221A (enExample)
AU (3) AU2017346879B2 (enExample)
CA (1) CA3042423A1 (enExample)
CL (1) CL2019001047A1 (enExample)
DK (1) DK3529360T3 (enExample)
ES (1) ES2982911T3 (enExample)
FI (1) FI3529360T3 (enExample)
HR (1) HRP20240930T1 (enExample)
HU (1) HUE067712T2 (enExample)
IL (1) IL266066A (enExample)
LT (1) LT3529360T (enExample)
MX (2) MX2019004573A (enExample)
PL (1) PL3529360T3 (enExample)
PT (1) PT3529360T (enExample)
RS (1) RS65725B1 (enExample)
SI (1) SI3529360T1 (enExample)
WO (1) WO2018075658A1 (enExample)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112015013105B1 (pt) 2012-12-05 2022-02-08 Alnylam Pharmaceuticals, Inc Agente de rnai de fita dupla capaz de inibir a expressão de pcsk9, seus usos, composição farmacêutica e método de inibição da expressão de pcsk9 em uma célula in vitro
EP3340994A1 (en) 2015-08-25 2018-07-04 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
HRP20240930T1 (hr) 2016-10-18 2024-10-11 Novartis Ag Postupci za prevenciju kardiovaskularnih događaja smanjenjem proteina proproteinske konvertaze suptilizin/keksin tipa 9 (pcsk9)
US11597744B2 (en) 2017-06-30 2023-03-07 Sirius Therapeutics, Inc. Chiral phosphoramidite auxiliaries and methods of their use
HRP20250277T1 (hr) 2017-12-01 2025-05-09 Suzhou Ribo Life Science Co., Ltd. Dvolančani oligonukleotid, sastav i konjugat koji sadrži dvolančani oligonukleotid, postupak njihove pripreme i upotreba
CN118291456A (zh) 2017-12-01 2024-07-05 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
WO2019105414A1 (zh) 2017-12-01 2019-06-06 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
CN110944675B9 (zh) 2017-12-01 2024-08-09 苏州瑞博生物技术股份有限公司 一种核酸、含有该核酸的组合物与缀合物及制备方法和用途
JP7360716B2 (ja) 2017-12-01 2023-10-13 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物および複合体ならびに調製方法と使用
CN110959011B (zh) 2017-12-29 2023-03-28 苏州瑞博生物技术股份有限公司 缀合物及其制备方法和用途
WO2020038377A1 (zh) 2018-08-21 2020-02-27 苏州瑞博生物技术有限公司 一种核酸、含有该核酸的药物组合物和缀合物及其用途
JP7376952B2 (ja) 2018-09-30 2023-11-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド ｓｉＲＮＡ複合体及びその調製方法と使用
JP7507495B2 (ja) 2018-12-28 2024-06-28 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、当該核酸を含む組成物及び複合体ならびに調製方法と使用
WO2020150473A2 (en) 2019-01-18 2020-07-23 Dogma Therapeutics, Inc. Pcsk9 inhibitors and methods of use thereof
BR112021013924A2 (pt) 2019-01-18 2021-09-21 Astrazeneca Ab Inibidores de pcsk9 e métodos de uso do mesmo
CN113286888B (zh) * 2019-05-22 2023-12-22 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
JP7610848B2 (ja) 2019-05-22 2025-01-09 スーチョウ リボ ライフ サイエンス カンパニー、リミテッド 核酸、薬物組成物及び複合体ならびに調製方法と使用
CN113227376B (zh) 2019-05-22 2024-04-09 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
CN113795582B (zh) 2019-05-24 2024-05-24 苏州瑞博生物技术股份有限公司 核酸、药物组合物与缀合物及制备方法和用途
US20230183694A1 (en) 2020-03-16 2023-06-15 Argonaute RNA Limited Antagonist of pcsk9
CN115572726A (zh) * 2021-06-21 2023-01-06 上海君实生物医药科技股份有限公司 一种抑制PCSK9基因表达的siRNA及其用途
WO2023241591A1 (zh) * 2022-06-14 2023-12-21 大睿生物医药科技(上海)有限公司 调控PCSK9基因活性的siRNA分子
JP2025531341A (ja) * 2022-09-19 2025-09-19 カイロンノヴァ （シャーメン） バイオファーマ カンパニー，リミテッド 炭水化物－オリゴヌクレオチド複合体、薬物組成物および治療への応用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506240A (ja) 2012-12-05 2016-03-03 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＰＣＳＫ９ｉＲＮＡ組成物及びその使用方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7605251B2 (en) * 2006-05-11 2009-10-20 Alnylam Pharmaceuticals, Inc. Compositions and methods for inhibiting expression of the PCSK9 gene
EP3340994A1 (en) * 2015-08-25 2018-07-04 Alnylam Pharmaceuticals, Inc. Methods and compositions for treating a proprotein convertase subtilisin kexin (pcsk9) gene-associated disorder
HRP20240930T1 (hr) 2016-10-18 2024-10-11 Novartis Ag Postupci za prevenciju kardiovaskularnih događaja smanjenjem proteina proproteinske konvertaze suptilizin/keksin tipa 9 (pcsk9)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016506240A (ja) 2012-12-05 2016-03-03 アルナイラム ファーマシューティカルズ， インコーポレイテッドＡｌｎｙｌａｍ Ｐｈａｒｍａｃｅｕｔｉｃａｌｓ， Ｉｎｃ． ＰＣＳＫ９ｉＲＮＡ組成物及びその使用方法

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
Circulation, 2014, Vol. 130, No. Suppl. 2, #11936
Drugs, 2021.2, Vol.81, No.3, pp.389-395
N. Engl. J. Med., 2017.1, Vol.376, No.1, pp.41-51
N. Engl. J. Med., 2017.4.13, Vol.376, No.15 , pp.1430-1440
心臓, 2013, Vol.45, No.6, pp.651-656

Also Published As

Publication number Publication date
BR112019007843A2 (pt) 2019-10-01
SI3529360T1 (sl) 2024-08-30
EP4397311A2 (en) 2024-07-10
AU2026203584A1 (en) 2026-05-28
KR20190077411A (ko) 2019-07-03
JP2022109948A (ja) 2022-07-28
DK3529360T3 (da) 2024-07-15
AU2023263519B2 (en) 2026-02-12
CN119318663A (zh) 2025-01-17
JP2025016469A (ja) 2025-02-04
JP2019531357A (ja) 2019-10-31
US20260108631A1 (en) 2026-04-23
EP3529360B1 (en) 2024-04-17
EP4397311A3 (en) 2024-10-16
MX2024004495A (es) 2024-05-08
KR20240067272A (ko) 2024-05-16
PL3529360T3 (pl) 2024-08-26
JP7850215B2 (ja) 2026-04-22
AU2023263519A1 (en) 2023-12-07
EP3529360A1 (en) 2019-08-28
MX2019004573A (es) 2019-10-07
IL266066A (en) 2019-06-30
JP7566815B2 (ja) 2024-10-15
ES2982911T3 (es) 2024-10-18
AU2017346879B2 (en) 2023-11-30
PT3529360T (pt) 2024-07-12
FI3529360T3 (fi) 2024-07-11
CA3042423A1 (en) 2018-04-26
LT3529360T (lt) 2024-07-25
US20180104360A1 (en) 2018-04-19
CN119700800A (zh) 2025-03-28
HUE067712T2 (hu) 2024-11-28
AU2017346879A1 (en) 2019-05-23
CN119345221A (zh) 2025-01-24
KR20250171391A (ko) 2025-12-08
JP2026062719A (ja) 2026-04-10
US20210093736A1 (en) 2021-04-01
HRP20240930T1 (hr) 2024-10-11
RS65725B1 (sr) 2024-08-30
CL2019001047A1 (es) 2020-05-08
WO2018075658A1 (en) 2018-04-26
CN110088283A (zh) 2019-08-02

Similar Documents

Publication Publication Date Title
JP7566815B2 (ja) プロタンパク質転換酵素サブチリシンケキシン９（ｐｃｓｋ９）タンパク質の低減により心血管イベントを予防するための方法
JP5964821B2 (ja) 痛風と高尿酸血症の処置
JP6568052B2 (ja) 心不全を治療するためのニューレグリンの徐放
JP2018203747A5 (enExample)
AU2014229985B2 (en) Methods of treating colorectal cancer
KR20240040767A (ko) His 저감반응자의 치료
JP2026021335A (ja) ａｐｏ（ａ）を標的化するコンジュゲートアンチセンス化合物を用いて心血管事象のリスクを低減する方法
JP2020535161A (ja) 組換えエクトヌクレオチドピロホスファターゼ／ホスホジエステラーゼ（ｎｐｐ１）を使用して心血管機能を改善し、心血管疾患を処置するための方法。
HK40113597A (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
TW202434264A (zh) 降低一級預防受試者中重大不良心血管事件風險之方法
BR112019007843B1 (pt) Métodos para prevenção de eventos cardiovasculares através da redução de proteína pró-proteina convertase subtilisina/quexina tipo 9 (pcsk9)
EA040947B1 (ru) Способы профилактики явлений со стороны сердечно-сосудистой системы посредством снижения содержания белка пропротеиновой конвертазы субтилизин-кексинового типа 9 (pcsk9)
HK40013430B (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
HK40013430A (en) Methods for preventing cardiovascular events through proprotein convertase subtilisin kexin 9 (pcsk9) protein reduction
AU2019268333A1 (en) Treating solid tumors with bromodomain inhibitors
WO2026062050A1 (en) Obicetrapib for use in methods for treating a subject having heterozygous familial hypercholesterolemia (hefh) and/or atherosclerotic cardiovascular disease (ascvd)
KR20260042531A (ko) Pcsk9 억제제를 이용하여 콜레스테롤 관련 질환을 치료 또는 예방하기 위한 방법
NZ792465A (en) Methods for preventing cardiovascular events through proprotein convertase
US20110262398A1 (en) Cardiac treatment using anti-fibrotic agents

Legal Events

Date Code Title Description
RD03 Notification of appointment of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7423

Effective date: 20200911

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20200914

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20200911

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201016

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201016

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210910

A871 Explanation of circumstances concerning accelerated examination

Free format text: JAPANESE INTERMEDIATE CODE: A871

Effective date: 20210910

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211019

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220113

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220315

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220419

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20220419

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220517

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220812

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220926

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20221025

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20221118

R150 Certificate of patent or registration of utility model

Ref document number: 7181881

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

S111 Request for change of ownership or part of ownership

Free format text: JAPANESE INTERMEDIATE CODE: R313113

R350 Written notification of registration of transfer

Free format text: JAPANESE INTERMEDIATE CODE: R350

R153 Grant of patent term extension

Free format text: JAPANESE INTERMEDIATE CODE: R153

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250